Credit Suisse shared with clients the firm's strategic updates to biotechnology stock picks in its second-quarter earnings preview.
"We have reviewed our models and made several updates into the quarter," wrote Credit Suisse analyst Alethia Young. "On a macro level, the most common questions we get on the space are when we think M&A will begin to pick up. Drug pricing reform also remains a topic of focus."
Here are three companies that Credit Suisse discussed along with their price targets.